Oncology Data Advisor

In May 2023, the FDA granted approval to epcoritamab, a CD3-redirecting, CD20-targeting bispecific antibody, for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. Following the approval, Oncology Data Advisor® spoke with Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Institute and one of the investigators of the EPCORE NHL-1 trial, on which the approval was based, to learn more about the efficacy and safety of epcoritamab and its burgeoning role in the treatment of relapsed/refractory DLBCL.